Immunohistochemistry as a practical tool in molecular pathology

Archives of Pathology and Laboratory Medicine

Volumn 140, Issue 8, 2016, Pages 766-769

  Sheffield, Brandon S ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CLASSIFICATION; EARLY CANCER DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MOLECULAR PATHOLOGY; NEOPLASMS; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PATHOLOGY, CLINICAL; PATHOLOGY, MOLECULAR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84980329213     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2015-0453-RA     Document Type: Conference Paper

References (47)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;148(3803):162-165.
2. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/new-overxpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16(8): 2659-2671.
3. Park Y, Moryama A, Kithara T, Yoshida Y, Urita T, Kato R. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors. Anticancer Agents Med Chem. 2012;12(6):672-677.
4. Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
5. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
6. Srlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874.
7. Chia SK, Bramwell VH, Tu D, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012;18(16):4465-4472
8. Kittaneh M, Montero AJ, Glück S. Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer. 2013;5(1):61-70.
9. Polley MY, Leung SC, Gao D, et al. An international study to increase concordance in Ki67 scoring. Mod Pathol. 2015;18(6):778-786.
10. Lakhani SR, Reis-Filho JS, Fulford L, et al; Breast Cancer Linkage Consortium. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11(14):5175-5180.
11. Won JR, Gao D, Chow C, et al. A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Mod Pathol. 2013;26(11):1438-1450.
12. Bass AJ, Thorsson V, Shmulevich I, et al; for Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma [published correction online September 10, 2014]. Nature. 2014;513(7517):202-209.
13. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1992;251(5000):1451-1455.
14. Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond [published correction appears in JAMA Oncol. 2015;1(1):110]. JAMA Oncol. 2015;1(1):23-32.
15. Sheffield BS, Garratt J, Kalloger SE, et al. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation. Arch Pathol Lab Med. 2014;138(11):1495-1502.
16. Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010; 376(9742):687-697.
17. Halling KC, Harper J, Moskaluk CA, et al. Origin of microasatellite instability in gastric cancer. Am J Pathol. 1999;155(1):205-211.
18. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol. 1992;140(4):769-774.
19. Kandoth C, Schultz N, Cherniack AD, et al; Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73.
20. Garg K, Leitao MM Jr, Wynveen CA, et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol. 2010;23(1):80-92.
21. Chiaravalli AM, Furlan D, Facco C, et al. Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadJournal style is to include both the percentage and the numbers that make up that percentage in all proportions. In the sentence that begins, astrocytosis, please provide the percentage, where indicated. ic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch. 2001;438(1):39-48.
22. Bakhsh S, Kinloch M, Hoang LN, et al. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. Histopathology. 2016;68(6):916-924.
23. Hoang LN, McConechy MK, Kobel M, et al. Polymerase epsilon exonuclease domain mutations in ovarian endometrioid carcinoma. Int J Gynecol Cancer. 2015;25(7):1187-1193.
24. Lynch HT, Lynch PM. Clinical selection of candidates for mutational testing for cancer susceptibility. Oncology. 2006;20(1):29-34.
25. Jin M, Hampel H, Zhou X, Schunemann L, Yearsley M, Frankel WL. BRAV V600E mutation analysis simplifies the testing algorithm for Lynch syndrome. Am J Clin Pathol. 2013;140(2):177-183.
26. Cui D, Cao D, Yang Y, Qui M, Huang Y, Yi C. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies. Mol Biol Rep. 2014;41(3):1291-1298.
27. Vasen HFA, Mecklin JP, Meera Khan P, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICGHNPCC). Dis Colon Rectum. 1991;34(1):424-425.
28. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261-268.
29. American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society; 2013.
30. Caldés T, Godino J, Sanchez A, et al. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer. Oncol Rep. 2004;12(3): 621-629.
31. Riazy M, Kalloger SE, Sheffield BS, et al. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Mod Pathol. 2015;28(10):1383-1389.
32. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatchrepair deficiency. N Eng J Med. 2015;372(26):2509-2520.
33. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577-580.
34. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708-710.
35. Valsangkar N, Sehdev A, Misra S, Zimmers TA, O'Neil BH, Koniaris LG. Current management of gastrointestinal stromal tumors: surgery, current biomarkers, mutations, and therapy. Surgery. 2015;158(5):1149-1164.
36. Gill AJ, Chou A, Vilain R, et al. Immunohistochemistry for SDHB divides gastrointestinal tumors (GISTs) into 2 distinct types. Am J Surg Pathol. 2010;24(5): 636-644.
37. Cutz JC, Craddock KJ, Torlakovic E, et al. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. J Thorac Oncol. 2014;9(9):1255-1263.
38. Sholl LM, Sun H, Butaney M, et al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol. 2013; 37(9):1441-1449.
39. Mohajeri A, Tayebwa J, Collin A, et al. Comprehensive genetic analysis identified a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer. 2013;52(10):873-876.
40. Cheah AL, Billings SD, Goldblum JR, Carver P, Tanas MZ, Rubin BP. STAT6 rabbit monoclonal antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics. Pathology. 2014;46(5):389-395.
41. Sheffield BS, Hwang HC, Lee AF, et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015;39(7)977-982.
42. Hwang HC, Sheffield BS, Rodriguez S, et al. Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol. 2016;40(1):120-126.
43. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37(1):61-65.
44. Bullock M, O'Neill C, Chou A, et al. Utilization of a MAB for BRAF (V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer. 2012; 19(6):779-874.
45. Cinicrope FA, Smyrk TC, Tougeron D, et al. Mutation-specific antibody detects mutant BRAF V600E protein expression in human colon carcinomas. Cancer. 2013;119(15):2765-2770.
46. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn. 2010;12(2):169-176.
47. Camelo-Piragua S, Jansen M, Ganguly A, et al. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol. 2011;70(2):110-115.